Skip to main content

Table 2 Patient characteristics

From: GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Pathological responseAll patients (pCR + Non-pCR)pCRNon-pCR
Age (years)
 Median (range)61.7 (33–69)65.3 (38–69)58.1 (34–68)
Tumor size stage
Nodal stage
  1. ESR Estrogen Receptor, pCR pathological Complete Response, TN triple negative